Displaying all 3 publications

Abstract:
Sort:
  1. Comparative bioavailability study of two controlled-release pentoxifylline tablet preparations
    Yuen KH, Wong JW, Peh KK, Julianto T, Choy WP
    Drug Dev Ind Pharm, 2000 Jul;26(7):803-7.
    PMID: 10872103
    The bioavailability of a generic preparation of pentoxifylline sustained-release (SR) tablet was evaluated in comparison with a proprietary product (Trental 400). For the study, 12 healthy male volunteers participated; the study was conducted according to a randomized, two-way crossover design. The bioavailability was compared using the parameters total area under the plasma level-time curve AUC0-infinity, peak plasma concentration Cmax, and time to reach peak plasma concentration Tmax. No statistically significant difference was observed between the values of the two products in all three parameters. The 90% confidence interval for the ratio of the logarithmic transformed AUC0-infinity values of the generic pentoxifylline over those of Trental 400 was found to lie between 0.83 and 1.00, while that of the parameter Cmax was between 0.91 and 1.29. In addition, elimination half-life t1/2 and apparent volume of distribution Vd were calculated. There was no statistically significant difference between the t1/2 Vd values obtained from the data of the two preparations.
    Matched MeSH terms: Hematologic Agents/administration & dosage; Hematologic Agents/blood; Hematologic Agents/pharmacokinetics*
  2. Management of Symmetrical Peripheral Gangrene
    Foead AI, Mathialagan A, Varadarajan R, Larvin M
    Indian J Crit Care Med, 2018 Dec;22(12):870-874.
    PMID: 30662227 DOI: 10.4103/ijccm.IJCCM_379_18
    Symmetrical peripheral gangrene (SPG) is a rare, debilitating disease that deserves more widespread concern among the medical fraternities. The objective of this review is to outline the etiology, pathology findings, and management practices of SPG. About 18%-40% mortality rate was reported, and survivors have high frequency of multiple limb amputations. SPG is the hallmark of disseminated intravascular coagulation (DIC). The main pathogenesis theory, to date, is microthrombosis associated with disturbed procoagulant-anticoagulant balance. The treatment of SPG is largely anecdotal and theoretically involves heparin-based anticoagulation and substitution of natural anticoagulants. Early recognition, prompt management of DIC, and underlying conditions may halt the progression of the disease. The multicenter randomized controlled trial should be set up to formulate the proper treatment guidelines.
    Matched MeSH terms: Hematologic Agents
  3. Fulltext Cocktail Protocol for Preparation of Platelet-Rich Fibrin Glue for Autologous Use
    Chenna D, Shastry S, Das S
    Malays J Med Sci, 2021 Feb;28(1):35-40.
    PMID: 33679218 DOI: 10.21315/mjms2021.28.1.5
    Background: Biomaterials containing platelets have been used to promote healing of ulcers and burns, as well as in implantology and maxillofacial and plastic surgery to achieve wound healing and tissue repair. Commercial devices to prepare autologous biomaterials involve diverse preparation methods that can have high production costs and low yields. Hence, we designed a protocol for preparation of large amounts of autologous platelet-rich fibrin (PRF) glue using conventional processing techniques for blood components.

    Methods: Autologous whole blood collected 72 h before surgery was processed to prepare platelet concentrates and cryoprecipitate. In a closed system, calcium was added to the cryoprecipitate to release autologous thrombin and generate a firm fibrin clot. The fibrin clot, platelets and calcium were then placed in a conical flask in which a PRF glue formed. The protocol was validated through determination of pre- and post-platelet counts and fibrinogen amounts in the product.

    Results: Platelets were recovered with 68% efficiency during the preparation. Essentially no platelets or fibrinogen were found in the supernatant of the PRF glue, suggesting that nearly all had been incorporated in a PRF glue having a relatively large (8 cm × 10 cm) size.

    Conclusion: The protocol described here is a cost-effective, simple and closed system that can be used to produce large-size PRF glue to promote repair of major surgical defects.

    Matched MeSH terms: Hematologic Agents
Related Terms
Filters
Contact Us

Please provide feedback to Administrator ([email protected])

External Links